Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2013
09/24/2013CA2670328C Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis c virus
09/24/2013CA2667210C 1,5-diphenyl-3-pyridinylmethylamino-1,5-dihydropyrrolidin-2-one as a cb-1 receptor modulator
09/24/2013CA2657275C Use of tylvalosin as antiviral agent
09/24/2013CA2655146C Benzamide derivatives and uses related thereto
09/24/2013CA2653753C Substituted prolinamides, production thereof and their use as medicaments
09/24/2013CA2640652C Novel coumarin derivative having antitumor activity
09/24/2013CA2633489C Compositions and methods for treating dermatological conditions
09/24/2013CA2632466C Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
09/24/2013CA2628461C Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
09/24/2013CA2615866C 4-chromenonyl-1,4-dihydropyridines and their use
09/24/2013CA2615855C 4-chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof
09/24/2013CA2615254C Combinations of pyrimidylaminobenzamide bcr-abl inhibitors and mtor inhibitors for the treatment of leukemia
09/24/2013CA2611609C Ampa receptor potentiators
09/24/2013CA2608184C N,n-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
09/24/2013CA2601454C Antibacterial 5,5'-disubstituted 3,3'-dialkoxy-2,2'-dihydroxy-1,1'-biphenyl compounds and related methods
09/24/2013CA2599826C Thienopyridine derivatives and the use thereof as hsp90 modulators
09/24/2013CA2598827C An hiv protease inhibitor solid dosage formulation for the treatment of hiv/aids under fasting conditions
09/24/2013CA2597748C Non steroidal glucocorticoid receptor modulators
09/24/2013CA2595517C Drug carrier and drug carrier kit for inhibiting fibrosis
09/24/2013CA2592345C Piperidine and azetidine derivatives as glyt1 inhibitors
09/24/2013CA2591321C Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
09/24/2013CA2584537C Formulations containing alkylphosphocholines using novel negative charge carriers
09/24/2013CA2584343C Pharmaceutical compositions comprising a camptothecin derivate
09/24/2013CA2578336C Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
09/24/2013CA2576993C Bisaryl-sulfonamides
09/24/2013CA2575737C Tanaproget derivatives, metabolites, and uses thereof
09/24/2013CA2568914C Therapeutic agents, and methods of making and using the same
09/24/2013CA2562235C Piperazinylpiperidine derivatives as chemokine receptor antagonists
09/24/2013CA2560387C Cytokine inhibitors
09/24/2013CA2545425C Azole-based kinase inhibitors
09/24/2013CA2540809C Lpa receptor agonists and antagonists and methods of use
09/24/2013CA2540598C Pyrazolopyridines and analogs thereof
09/24/2013CA2539567C Nutritional and therapeutic compositions to increase bodily glutathione levels
09/24/2013CA2533730C Methods for treatment of dermatological conditions
09/24/2013CA2497958C Zeolite y alkylation catalysts
09/24/2013CA2497452C Compositions and process for delivering an additive
09/24/2013CA2489090C Nutritional composition for detoxification and cancer prevention
09/24/2013CA2488394C Sulfur-containing proanthocyanidin oligomer composition and production method thereof
09/24/2013CA2480656C Bioadhesive directed somatic cell therapy
09/24/2013CA2476410C Methods to increase or decrease bone density
09/24/2013CA2474277C 2,4-pyrimidinediamine compounds and their uses
09/24/2013CA2471817C Labeling targeting agents with gallium-68 and gallium-67
09/24/2013CA2466697C Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
09/24/2013CA2434760C Differentiated cells suitable for human therapy
09/24/2013CA2425669C Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis
09/19/2013WO2013138787A1 Highly 6-substituted -2,4-diaminopyrimidines as inhibitors of anthrax
09/19/2013WO2013138783A1 A NOVEL RNAi MOLECULE DELIVERY PLATFORM BASED ON SINGLE-siRNA AND shRNA NANOCAPSULES
09/19/2013WO2013138753A1 Prodrugs of riluzole and their method of use
09/19/2013WO2013138748A1 Prevention of clostridium difficile infection in high risk patients
09/19/2013WO2013138744A1 Compositions for the treatment of skin disorders
09/19/2013WO2013138730A1 Polymeric conjugates of c1-inhibitors
09/19/2013WO2013138697A1 Methods and materials for treating cancer
09/19/2013WO2013138687A1 Positive allosteric modulators of mglur2
09/19/2013WO2013138666A1 Inhibitors of furin and other pro-protein convertases
09/19/2013WO2013138665A1 Inhibitors of furin and other pro-protein convertases
09/19/2013WO2013138662A1 Antisense conjugates for decreasing expression of dmpk
09/19/2013WO2013138628A2 Injectable ibuprofen formulation
09/19/2013WO2013138617A1 3,5-diaminopyrazole kinase inhibitors
09/19/2013WO2013138613A1 3,5-diaminopyrazole kinase inhibitors
09/19/2013WO2013138612A1 Synthesis and application of novel imaging agents conjugated to dpa 713 analogs for imaging inflammation
09/19/2013WO2013138602A1 An iloperidone metabolite for use in the treatment of psychiatric disorders
09/19/2013WO2013138600A1 Radioprotector compounds
09/19/2013WO2013138568A1 Liver x reception modulators
09/19/2013WO2013138565A1 Liver x receptor modulators
09/19/2013WO2013138563A1 Glycomimetics to inhibit pathogen-host interactions
09/19/2013WO2013138560A1 Treatment of cancer with tor kinase inhibitors
09/19/2013WO2013138557A1 Treatment of cancer with tor kinase inhibitors
09/19/2013WO2013138556A1 Treatment of cancer with tor kinase inhibitors
09/19/2013WO2013138553A1 Treatment of cancer with tor kinase inhibitors
09/19/2013WO2013138436A1 Cyclolic hydrazine derivatives as hiv attachment inhibitors
09/19/2013WO2013138430A1 Compounds and methods for treating leukemia
09/19/2013WO2013138427A1 Microvesicle-mediated delivery of therapeutic molecules
09/19/2013WO2013138411A1 Substances for reducing occurrence of major cardiac events comprising omega-3 polyunsaturated fatty acid or derivatives thereof and high-monacolin k content red yeast rice extract
09/19/2013WO2013138409A1 Red yeast rice extract high in monacolin k content
09/19/2013WO2013138407A1 Substances for reducing occurrence of major cardiac events comprising epa or derivatives thereof, optionally, dha or derivatives thereof and monacolin k
09/19/2013WO2013138396A1 Dihydropyridopyrimidine and dihydronaphthyridine derivatives as tyrosine kinase inhibitors of especially vegf and pdgf
09/19/2013WO2013138393A1 Method of treating ophthalmic conditions with kinase inhibitors
09/19/2013WO2013138361A1 Inhibitors of human ezh2, and methods of use thereof
09/19/2013WO2013138341A1 Topk inhibiting compounds
09/19/2013WO2013138322A1 Esketamine for the treatment of treatment-refractory or treatment-resistant depression
09/19/2013WO2013138306A1 Compositions and methods for treatment of pain
09/19/2013WO2013138236A1 2'- substituted carba-nucleoside analogs for antiviral treatment
09/19/2013WO2013138210A1 Substituted cyclic compounds and methods of use
09/19/2013WO2013138200A1 Green chemistry synthesis of the malaria drug amodiaquine and analogs thereof
09/19/2013WO2013138187A1 Broad spectrum antibiotic arylomycin analogs
09/19/2013WO2013138101A2 Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
09/19/2013WO2013138064A1 Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
09/19/2013WO2013137869A1 Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
09/19/2013WO2013137844A1 Method for isolating flavonoid dihydroquercetin (taxifolin) from conifer wood species
09/19/2013WO2013137839A1 Tablet formulation comprising dapagliflozin and extended release metformin
09/19/2013WO2013137832A1 Myostatin inhibitors
09/19/2013WO2013137778A1 Solid dosage form having neuroprotector, antiamnesic, antioxidant, antihypoxic, and antiischaemic activity (alternatives)
09/19/2013WO2013137748A1 Long acting compositions
09/19/2013WO2013137628A1 Novel diacylglycerol acyltransferase-2 inhibiting material, and use thereof
09/19/2013WO2013137627A1 Drug delivery conjugate capable of controlled release, and use thereof
09/19/2013WO2013137563A1 Pharmaceutical composition for preventing or treating tuberculosis
09/19/2013WO2013137514A1 Pharmaceutical composition for preventing and treating bone diseases, containing aminobenzoate derivative or pharmaceutically acceptable salt thereof
09/19/2013WO2013137495A1 Replication competent pseudo-type retrovirus vector system
09/19/2013WO2013137479A1 Decahydroquinoxaline derivatives and analogs thereof
09/19/2013WO2013137456A1 Antivirus composition
1 ... 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 ... 7860